Skip to main content

Table 8 Effect of C. azarolus var. eu- azarolus leaves extract on serum lipid profile, Atherogenic Index and LDL-C/HDL-C ratio in hyperlipidemic rats in hyperlipidemic rats (values are represented as Mean ± SEM)

From: Therapeutic potentials of Crataegus azarolus var. eu- azarolus Maire leaves and its isolated compounds

Group

Total cholesterol (mg/dl)

Triglyceride (mg/dl)

HDL-C (mg/dl)

LDL-C (mg/dl)

VLDL-C (mg/dl)

Atherogenic index

LDL - C/HDL - C

I

61.7 ± 2.4

60.5 ± 5.6

36.3 ± 1.1

22.0 ± 0.7

12.4 ± 0.5

1.7 ± 0.3

0.6 ± 0.02

II

84.5 ± 2.5#

127.5 ± 2.5#

26.0 ± 1.1#

39.1 ± 1.3#

16.9 ± 0.6#

3.25 ± 0.7

1.5 ± 0.2

III

61.5 ± 0.5** (−27.2%)

58.0 ± 2.1** (−54.5%)

33.5 ± 0.5** (+28.8%)

24.3 ± 1.1** (−37.9%)

12.3 ± 0.1* (−27.2%)

1.8 ± 0.2

0.7 ± 0.05

IV

78.3 ± 3.4 (−7.3%)

61.3 ± 6.9** (−51.9%)

30.2 ± 1.4* (+16.2%)

26.5 ± 0.6** (−32.2%)

15.7 ± 0.7 (−7.1%)

2.6 ± 0.6

0.9 ± 0.04

V

61.7 ± 1.8** (−27.0%)

49.0 ± 2.5** (−61.6%)

32.5 ± 0.6** (+25.0%)

25.2 ± 0.7** (−35.6%)

12.9 ± 0.4* (−23.7%)

1.9 ± 0.3

0.8 ± 0.05

  1. Group I: Control group received the vehicle, groups II-V were hyperlipidemic and received daily cholesterol (25 mg/kg/day) in oil at 10:00 am. Group II received cholesterol, group III received lovastatin, groups IV and V were given the plant extract at doses of 250 and 500 respectively. # p < 0.01 vs group I, * and ** p < 0.05 and 0.01 vs cholesterol induced hyperlipidemic control group respectively